Company intelligence / Profile preview

Atonco

Saint-Herblain, Pays de la Loire, France

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Atonco is advancing ATO-101, an astatine-211-labeled chimeric anti-CAIX antibody (girentuximab), in a Phase 1-2a clinical study for non-muscle invasive bladder cancer refractory to BCG and chemotherapy. Preclinical data supports efficacy in similar models.[2][3][5]

Therapeutic areas: Oncology
Modalities: Radiopharmaceutical
Industry: Biotech

Partnerships

IONETIXUniversity of Michigan Health

Beyond the preview

Go deeper on Atonco.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atonco.

Explore the full profile